INSTITUTION'S PROFILE
GlaxoSmithKline, Collegeville, PA, USA.
Publications (2)
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study.
Journal: The lancet. HIV
Publication date: 2023
Journal: The lancet. HIV
Publication Year: 2023
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.
Journal: The lancet. HIV
Publication date: 2022
Journal: The lancet. HIV
Publication Year: 2022